Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

This study is testing a new type of immune cell therapy — called CIML natural killer (NK) cell therapy — delivered directly into the abdomen to treat ovarian cancer that has come back after prior treatment. NK cells are immune cells that can recognize and destroy cancer cells. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with recurrent epithelial ovarian cancer (specifically high-grade serous, high-grade endometrioid, or clear cell type) - Your cancer shows measurable disease on scans - You have received at least 1 prior treatment and your cancer is resistant to or you cannot tolerate platinum-based chemotherapy - If you carry a BRCA1 or BRCA2 gene mutation, you must have previously tried a PARP inhibitor drug **You may NOT be eligible if:** - You have not received any prior treatment for ovarian cancer - You experienced severe (grade 3+) side effects from prior immunotherapy - You do not have measurable disease on scans Talk to your doctor to see if this trial is right for you.